Puma Biotechnology Stock: A Resurgent Biotech Play Gains Momentum

The biotechnology sector has a fresh standout performer as Puma Biotechnology undergoes a remarkable transformation. The company’s equity has surged impressively, posting gains exceeding 70 percent since the start of the year and consistently reaching new peaks. What fundamental drivers are propelling this powerful upward trend?

Puma Biotechnology’s quarterly financial performance illustrates a dramatic reversal of fortune. For the second quarter of 2025, the company reported a GAAP net income of $5.9 million, or $0.12 per share. This result starkly contrasts with the $4.5 million loss recorded during the same period last year. The adjusted profit picture appears even stronger, climbing to $7.5 million.

This financial success is built on a solid operational foundation. Revenue generated by its flagship product, NERLYNX, increased by 10.8 percent to... Read more...